Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

New report outlines long-term risks of prostate cancer treatment, highlighting potential impacts on quality of life and need ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

or “fadra”, as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona ...

The EORTC-NCI-AACR symposium is being held October ... with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, is a computationally designed human ...

during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $72 and keeps a Buy rating ...

So how should you respond when someone tells you they have cancer? As someone who has worked in cancer research for years, ...

These initial results were presented during the late-breaking oral session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 25, 2024. “We are ...

"We are thrilled to present preclinical data for ZW220 and ZW251 at the EORTC-NCI-AACR Conference," said Paul Moore, Ph.D., ...

or "fadra”, as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting”), in Barcelona, Spain (October 23-25, ...